Phase II/III Study of FK949E - Placebo-controlled, Double-blind, Parallel-group Comparative Study and Open-label, Non-controlled Extension Study in Bipolar Disorder Patients With Major Depressive Episodes

Trial Profile

Phase II/III Study of FK949E - Placebo-controlled, Double-blind, Parallel-group Comparative Study and Open-label, Non-controlled Extension Study in Bipolar Disorder Patients With Major Depressive Episodes

Completed
Phase of Trial: Phase II/III

Latest Information Update: 28 Mar 2017

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Bipolar I disorders; Bipolar II disorders
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 09 Aug 2016 Status changed from active, no longer recruiting to completed.
    • 09 Jul 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 22 Jan 2014 Planned number of patients changed from 600 to 340 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top